PMID-15134286 – AOD-9604 Clinical Development Review
Wilding J. AOD9604. Curr Opin Investig Drugs. 2004;5(4):400-405.
Quick Reference
| Property | Value |
|---|---|
| PMID | 15134286 |
| DOI | — |
| Year | 2004 |
| Journal | Current Opinion in Investigational Drugs |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of preclinical and early clinical data |
| Peptide(s) Studied | AOD-9604 |
Key Findings
- Comprehensive review of AOD9604 clinical development status as of 2004
- Phase IIa clinical trials for obesity were reported as underway by Metabolic Pharmaceuticals Ltd as of February 2002
- Summarized the preclinical evidence for oral bioavailability and weight reduction without GH-related side effects
- Noted the unique mechanism — a fragment of hGH (residues 177-191) with lipolytic but not somatotropic activity
- Positioned AOD9604 within the broader landscape of anti-obesity drug development at the time
Study Design
Narrative review article synthesizing published preclinical data, patent filings, and publicly available clinical development information for AOD9604. No original experimental data presented.
Limitations
- Review article, not primary research
- Clinical trial results from Phase IIa were not yet published at time of writing
- Relies partly on company press releases and patent information rather than peer-reviewed data
- Now over 20 years old — clinical development trajectory has changed significantly since publication
- Limited critical analysis of the preclinical data quality
Clinical Relevance
This review provides historical context for AOD9604's clinical development pathway. While the Phase II/III obesity trials ultimately did not lead to FDA approval, the safety data generated during clinical development contributed to AOD9604 receiving GRAS (Generally Recognized as Safe) status from the FDA for oral use as a food ingredient. This regulatory history is important context for current use of AOD9604 in clinical and research settings.
Related
#research #narrative-review #AOD-9604 #evidence-level-V